Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

被引:101
作者
Kajinami, K
Brousseau, ME
Ordovas, JM
Schaefer, EJ
机构
[1] Kanazawa Med Univ, Dept Cardiol, Uchinada, Ishikawa 9200293, Japan
[2] Tufts Univ, New England Med Ctr, Div Endocrinol Metab & Mol Biol, Lipid Res Lab, Boston, MA 02111 USA
[3] Tufts Univ, Human Nutr Res Ctr Aging, USDA, Lipid Metab Lab, Boston, MA 02111 USA
关键词
D O I
10.1016/j.amjcard.2004.01.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To test the hypothesis that variations in the multidrug resistance-1 gene influence the response to statin treatment, 2 prevalent polymorphisms (G2677T/A and C3435T) were examined in 344 hypercholesterolemic patients treated with atorvastatin (10 mg). The C3435T polymorphism was significantly, and independently associated with a smaller reduction in lowdensity lipoprotein cholesterol and with a larger increase in high-density lipoprotein cholesterol, relative to variant allele carriers, in a gender-specific manner. Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:1046 / 1050
页数:5
相关论文
共 18 条
  • [1] Berge KE, 2002, J LIPID RES, V43, P486
  • [2] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [3] New insights into the pharmacodynamic and pharmacokinetic properties of statins
    Corsini, A
    Bellosta, S
    Baetta, R
    Fumagalli, R
    Paoletti, R
    Bernini, F
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) : 413 - 428
  • [4] Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia
    Davidson, M
    McKenney, J
    Stein, E
    Schrott, H
    BakkerArkema, R
    Fayyad, R
    Black, D
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) : 1475 - 1481
  • [5] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
    Evans, WE
    McLeod, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 538 - 549
  • [6] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Fellay, J
    Marzolini, C
    Meaden, ER
    Back, DJ
    Buclin, T
    Chave, JP
    Decosterd, LA
    Furrer, H
    Opravil, M
    Pantaleo, G
    Retelska, D
    Ruiz, L
    Schinkel, AH
    Vernazza, P
    Eap, CB
    Telenti, A
    [J]. LANCET, 2002, 359 (9300) : 30 - 36
  • [7] The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
    Fromm, MF
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) : 1295 - 1310
  • [8] Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase - Further experimental evidence for a multisite model
    Garrigos, M
    Mir, LM
    Orlowski, S
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 244 (02): : 664 - 673
  • [9] Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    Hoffmeyer, S
    Burk, O
    von Richter, O
    Arnold, HP
    Brockmöller, J
    Johne, A
    Cascorbi, I
    Gerloff, T
    Roots, I
    Eichelbaum, M
    Brinkmann, U
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3473 - 3478
  • [10] Kalow W, 1998, PHARMACOGENETICS, V8, P283